Insights into immune checkpoint-related pneumonitis: a case series from Massachusetts General Hospital
OA Version
Citation
Abstract
While checkpoint inhibitor immunotherapy has afforded patients with cancer a new and effective treatment option, it also comes with potentially fatal side effects such checkpoint-induced pneumonitis. Due the relatively rare and severe nature of this adverse event, mechanisms of pneumonitis are poorly understood. Therefore, research needs to be focused on how we can better risk stratify and predict outcomes for patients receiving checkpoint inhibitors. This case series focuses on patients with checkpoint induced pneumonitis and their outcomes in the context of pulmonary co-morbidities. We found that patients with pre-existing pulmonary conditioned had a faster and more severe outcomes than their counterparts. This further underscores the importance of understandings risk factors, treatment options and early monitoring for these patients.
Description
2025